Oral lesions among persons with HIV disease with and without highly active antiretroviral therapy in southern India

Journal of Oral Pathology and Medicine

Volumn 36, Issue 3, 2007, Pages 136-141

  Umadevi, K M R ^a   Ranganathan, K ^a   Pavithra, S ^a   Hemalatha, R ^a   Saraswathi, T R ^a   Kumarasamy, N ^b   Solomon, Suniti ^b   Greenspan, John S ^c  

^a RAGAS DENTAL COLLEGE AND HOSPITAL   (India)

^b VHS Medical Centre India   (India)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Generic HAART; HIV; India; Oral lesions

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; APHTHOUS ULCER; ARTICLE; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; ERYTHEMATOUS CANDIDIASIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MOUTH LESION; PIGMENTATION; PREVALENCE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS CANDIDIASIS; TERTIARY HEALTH CARE; THRUSH; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS, ORAL; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INDIA; MALE;

EID: 33846994680     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2006.00505.x     Document Type: Article

References (37)

1. Fighting AIDS. Available at: http://www.theglobalfund.org/en/about/aids.
2. National AIDS Control Organization. 2004. Available at: http://www.nacoonline.org/facts_hivestimates04.htm
3. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy (HAART) decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.
4. Kumarasamy N, Solomon S, Sreekanth KC, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in Southern India. Clin Infect Dis 2005; 41: 1525-8.
5. Greenspan JS. Sentinels and Signposts: The epidemiology and significance of the oral manifestations of HIV disease. Oral Dis 1997; 3 (Suppl. 1): 13-7.
6. Ranganathan K, Reddy BVR, Kumarasamy N, Solomon S, Viswanathan R, Johnson NW. Oral lesions and conditions associated with human immunodeficiency virus infection in 300 South Indian patients. Oral Dis 2000; 6: 152-7.
7. Begg MD, Panageas KS, Mitchell-Lewis D, Bucklan RS, Phelan JA, Lamster IB. Oral lesions as markers of severe immunosuppression in HIV-infected homosexual men and injection drug users. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82: 276-83.
8. Greenspan D, Komaroff E, Redford M, et al. Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2000; 25: 44-50.
9. Kerdpon D, Pongsiriwet S, Pangsomboon K, et al. Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in Northern and Southern Thai patients. Oral Dis 2004; 10: 138-44.
10. Arribas JR, Hernandez-Albujar S, Gonzalez-Garcia JJ, et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS 2000; 14: 979-85.
11. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 1999; 29: 336-41.
12. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001; 357: 1411-2.
13. Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, Gonzalez-Ramirez I, Ponce de Leon S. The changing clinical spectrum of Human Immunodeficiency Virus (HIV)-related oral lesions in 1000 consecutive patients: A 12-year study in a referral center in Mexico. Medicine 2003; 82: 39-50.
14. Greenspan D, Gange SJ, Phelan JA, et al. Incidence of oral lesions in HIV-1 infected women: reduction with HAART. J Dent Res 2004; 83: 145-50.
15. Nicolatou-Galitis O, Velegraki A, Paikos S, et al. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis 2004; 10: 145-50.
16. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. Human papilloma virusassociated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: An emerging infection. Clin Infect Dis 2002; 34: 641-8.
17. Ranganathan K, Umadevi M, Saraswathi TR, Kumarasamy N, Solomon S, Johnson N. Oral lesions and conditions associated with Human Immunodeficiency Virus infection in 1000 South Indian patients. Ann Acad Med Singapore 2004; 33 (Suppl. 4): 37-42.
18. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr 2006; 41: 53-8.
19. World Health Organization scaling of antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach. 2003. Available at: http://www.who.int/3by5/publications/ documents/arv_guidelines/en/.
20. Greenspan JS, Barr CE, Sciubba JJ, Winkler JR. For the USA Oral AIDS Collaborative Group. Oral manifestations of HIV infection. Definitions, diagnostic criteria and principles of therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1992; 73: 142-4.
21. EC Clearinghouse on oral problems related to HIV infection and WHO collaborating centre on oral manifestations of the immunodeficiency virus. Classification and diagnostic criteria for oral lesions in HIV infection. Oral Pathol Med 1993; 22: 289-91.
22. Ceballos-Salobreña A, Gaitan-Cepeda LA, Ceballos-Garcia L, Lezama Del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: A new face of oral AIDS. AIDS Patient Care STDs 2000; 14: 627-35.
23. Ceballos-Salobreña A, Gaitan-Cepeda L, Ceballos-Garcia L, Samaranayake LP. The effect of antiretroviral therapy on the prevalence of HIV-associated oral candidiasis in a Spanish cohort. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97: 345-50.
24. Tappuni AR and Fleming GJ. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: A UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 623-8.
25. Eyeson D, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KA. Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. J Oral Pathol Med 2002; 31: 169-74.
26. Greenwood I, Zakrzewska JM and Robinson PG. Changes in the prevalence of HIV-associated mucosal disease at a dedicated clinic over 7 years. Oral Dis 2002; 8: 90-4.
27. Cassone A, Tacconelli E, De Bernardis F, et al. Antiretroviral therapy with protease inhibitors has an early immune reconstitution-independent beneficial effect on candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis 2002; 185: 188-95.
28. Bower M, Fox P, Fife K, et al. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13: 2105-11.
29. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss cohort study. JAMA 1999; 282: 2220-6.
30. Bart PA, Rizzardi GP, Tambussi G, et al. Immunological and virological responses in HIV-1 infected adults at early stage of established infection treated with HAART. AIDS 2000; 14: 1887-97.
31. Blignaut E, Patton LL, Nittayanta W, Ramirez-Amador V, Ranganathan K, Chattopadhyay A. (A3) HIV phenotypes, oral lesions, and management of HIV-related disease. Adv Dent Res 2006; 19: 122-9.
32. Panther LA, Schiecht HP, Dezube BJ. Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read 2005; 15: 79-82, 85-6, 88, 91 (Review).
33. Kreimer AR, Alberg AJ, Daniel R, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 2004; 189: 686-98.
34. Kreimer AR, Alberg AJ, Viscidi R, Gillison ML. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis 2004; 4: 247-56.
35. D'Costa J, Saranath D, Dedhia P, Sanghvi V, Mehta AR. Detection of HPV-16 genome in human oral cancers and potentially malignant lesions from India. Oral Oncol 1998; 34: 413-20.
36. Coutlée F, Trottier A-M, Ghattas G, et al. Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus: 1995. Presented in part at the 14th International Papillomavirus Conference, Quebec City, Canada, 1995.
37. Gaitan-Cepeda LA, Martinez-Gonzaiez M, Ceballos-Salobrena A. Oral candidiasis as a clinical marker of immune failure in patients with HIV/AIDS on HAART. AIDS Patient Care STDs 2005; 19: 70-7.